Beginning the week with a new article at Seeking Alpha:
Merrimack Pharmaceuticals Should Drive Higher In 2016 On Onivyde And Pipeline
I must admit I was a bit dubious about Merrimack when I first came across it in the distant past. I took a long time and did quite a bit of research before initially investing in September of 2014. The stock is down, since then (I bought at $7.97), but the progress has been great. I think MACK is a huge bargain at this point, though not without it risks.
This afternoon AMD reports Q4 earnings. I don't expect anything spectacular, but I do hope for some optimism about 2016. AMD is one of my few remaining semiconductor stocks. Almost my entire portfolio is in biotechnology now.
I am a journalist & investor. I try to be honest and pick good stocks for my own portfolio, but that does not mean my portfolio is right for you, nor is any individual stock.